

WHO hepatitis screening, care, and treatment guidelines (draft)

globalhepatitis
programme

Dr. Stefan Wiktor, Team Lead



World Health
Organization

Global Hepatitis Framework



Axis 1: Partnerships, resource mobilization and communication

Strategic axis 1. Building partnerships, raising awareness and mobilizing resources



Axis 2: Data for policy and action

Strategic axis 2. Data for policy and action

Axis 3: Prevention of virus transmission



Strategic axis 3. Prevention of transmission




Strategic axis 4. Screening, care and treatment

Axis 4: Screening, care and treatment

Context for the guidelines

- Focus on low- and middle-income countries
- Huge geographical difference in standards of care
- Rapidly changing therapeutic environment
- Lack of existing WHO hepatitis C guidelines
- WHO guidelines have a political dimension
- Strict evidence-based process for WHO guidelines

Guideline development at WHO



GRADE




Elements of WHO recommendations

- **Strength of evidence:**
 - High quality: further research is very unlikely to change the confidence in the estimate of effect
 - Moderate quality: further research is likely to have an important impact on the confidence in the estimate of effect and may change the estimate
 - Low quality: further research is very likely to have an important impact on the confidence in the estimate of effect and is likely to change the estimate
 - Very low quality: uncertainty about the estimate.
- **Strength of recommendation:**
 - Strong – confidence that the benefits of the intervention outweighed the risks).
 - Conditional - benefits of the intervention probably outweighed the risks

Considerations for strength of recommendation

Criteria	Questions
Problem	Is the problem a priority? Are a large number of people affected?
Benefits and Harms	Are the desirable anticipated effects large? Are the undesirable anticipated effects small? What is the overall certainty of this evidence?
Values	How certain is the relative importance of the desirable and undesirable outcomes? Are the desirable effects large relative to the undesirable effects?
Resource Use	Are the resources required small? Is the incremental cost small relative to the net benefits?
Equity	What would be the impact on health inequities?
Acceptability	Is the option acceptable to key stakeholders?
Feasibility	Is the option feasible to implement?

Topics for WHO hepatitis C screening, care and treatment guidelines



Recommendations

- Screening of at-risk groups
- Confirmation of chronic infection
- Alcohol-reduction intervention
- Non-invasive fibrosis assessment
- Assess all persons with chronic HCV for treatment
- Peg-IF and ribavirin
- DAAs



Other considerations

- Genotyping
- When to start
- Placing these recommendations in the context of known prevention interventions
- Special populations
 - Children
 - Persons who inject drugs
 - HIV co-infection
- Implementation and operational considerations




Next steps

- Peer review
- Technical editing
- Modification to include recommendation on new DAAs
- Approval by Guidelines Review Committee
- Pre-production
- Translation
- Launch at EASL 2014
- Adapt and update




Axis 4: WHO's role in improving access to hepatitis therapy



Status of WHO hepatitis-related guidelines development

Guidelines	Status	Publication date
Hepatitis C treatment	Draft document	April 2014
Hepatitis B treatment	Guidelines Development Group formulating questions	December 2014
Hepatitis surveillance	Draft document in review	Mid 2014
Hepatitis screening and testing		

WHO-GHP approach to strengthening national hepatitis control plans



Thank you

globalhepatitis
programme

